PMC

The possible future landscape for diagnosis and monitoring of acute myeloid leukemia at various time points during treatment and subsequent surveillance. The current schema follows the guidelines of the National Comprehensive Cancer Network and others. In the future, we posit that advances in flow cytometry and sequencing (and possibly imaging) may circumvent our current reliance on morphology and cytogenetics. Though the current sensitivity of bone marrow testing is generally 10-fold higher than in the peripheral blood, many tests may be done on peripheral blood only in the future. Timing of surveillance monitoring for measurable residual disease on the peripheral blood will likely depend on the abnormalities being followed for a particular patient.